<DOC>
	<DOCNO>NCT02688829</DOCNO>
	<brief_summary>This small-scale pilot clinical study Rapamycin-Eluting Coronary Stent System Microport first time assess preliminary safety feasibility use human body . And provide evidence subsequent large-scale , multi-center , randomize control clinical trial , provide basis formal application product China .</brief_summary>
	<brief_title>The First-In-Man Pilot Study Firehawk</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . 1875 year age , male nonpregnant female ; 2 . With silent ischemia evidence , patient stable unstable angina , patient old myocardial infarction ; 3 . Total number target lesion 1 ; 4 . Target lesion length ≤ 30mm ( Visual ) ; target lesion diameter 2.25mm 4.0mm ; 5 . Visual assessment target lesion diameter stenosis ≥ 70 % , TIMI blood flow≥1 ; 6 . Each target lesion may cover single stent ; 7 . Patients indication coronary artery bypass graft surgery ; 8 . To understand purpose testing , voluntary inform consent , patient undergo invasive imaging followup . 1 . Within 1 month acute myocardial infarction ; 2 . Chronic total occlusion ( TIMI grade 0 flow surgery ) , leave main coronary artery disease , mouth lesion , multiplevessel lesion , branch diameter ≥ 2.5mm bifurcation lesion vascular lesion bridge ; 3 . Severe calcify lesion successfully expand distort lesion suitable stent delivery ; 4 . Instent Restenosis lesion ; 5 . Intracoronary implantation brand stent within 1 year ; 6 . Severe congestive heart failure ( NYHA class III ) , leave ventricular ejection fraction &lt; 40 % ( ultrasound leave ventricular angiography ) ; 7 . Preoperative renal function serum creatinine &gt; 2.0mg/DL ; 8 . Bleeding , active gastrointestinal ulcer , brain hemorrhage subarachnoid hemorrhage half year history ischemic stroke , antiplatelet agent would allow anticoagulant therapy contraindication patient undergo antithrombotic therapy ; 9 . Aspirin , clopidogrel , heparin , contrast agent , poly lactic acid polymer rapamycin allergy ; 10 . The patient 's life expectancy le 12 month ; 11 . Top participate drug medical device meet primary study endpoint clinical trial time frame ; 12 . Researchers determine patient compliance poor , unable complete study accordance requirement ; 13 . Heart transplantation patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stent , percutaneous coronary intervention</keyword>
</DOC>